Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol and Furosemide in Transient Tachypnea of Newborn
NCT03208894Phase 3Completed
- Sponsor
- Combined Military Hospital
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of salbutamol and furosemide in transient tachypnea of the newborn (TTN) (4 arms), sponsored by Combined Military Hospital. Primary endpoint: Duration of oxygen requirement up to 6 months. Started Nov 2016; status: completed.
02
Drugs
salbutamolfurosemide
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on NCT03208894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208894.